SARS-CoV-2 vaccination response in people living with HIV

Recruiting

• Conditions: coronavirus; SARS-CoV-2 virus; 10021460; 10047438

• Registration Number: NL-OMON52193
• Lead Sponsor: OLVG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 1650

Inclusion Criteria

- 18 years or older
- Confirmed HIV infection
- Selected by national regulations for SARS-CoV2 vaccination
- Active participant in the follow-up of the Stichting HIV monitoring

Exclusion Criteria

a history of a previous SARS-CoV2 infection (proven by PCR or positive
serology). For participation in substudy previous SARS-CoV2 is no reason for
exclusion

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main study: primary vaccination regimen<br /><br>Primary Outcome:<br /><br>1. Antibody response against SARS-CoV-2 in PLWH 4 weeks after the completed<br /><br>vaccination schedule with one of the two available mRNA vaccines (BNT162b2 or<br /><br>mRNA-1273) compared to non-HIV healthy controls.</p><br>